Trial reportAesthetic surgery journal2026
Efficacy and Safety of a Poly-L-Lactic Acid Filler for Temporal Augmentation: A Randomized, No-treatment Control, Evaluator-blinded, Multicenter Study.
Trial report in Aesthetic surgery journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundTemple hollowing represents a prevalent aesthetic concern traditionally addressed with autologous fat grafting or hyaluronic acid fillers. Poly-L-lactic acid (PLLA) offers gradual, collagen-mediated volumization and is increasingly utilized for soft tissue augmentation. Nevertheless, to date, no approved study has evaluated its use for temporal augmentation.
objectivesThe aim of this study was to evaluate the efficacy and safety of a PLLA facial filler for the augmentation of temple hollowing.
methodsThis randomized, no-treatment control, evaluator-blinded, multicenter clinical trial enrolled 174 participants with moderate to severe temple hollowing, randomized 2:1 to the treatment or control group. The treatment group received 2 to 3 sessions of PLLA bilateral temporal injections with 12-month follow-up, and the control group received no treatment within 6 months after randomization. Efficacy was assessed with the Allergan Temple Hollowing Scale (ATHS), Global Aesthetic Improvement Scale (GAIS), 3-dimensional (3D) volume change of temples, and participant-reported satisfaction. Safety evaluations included adverse events (AEs), injection-site reactions, vital signs, and laboratory tests.
resultsAt Month 6, 96.5% of participants in the treatment group achieved an at least 1-grade improvement on the ATHS, in contrast to 0% in the control group (P < .0001). Consistent and significant improvements were observed across all secondary endpoints, including ATHS efficacy rates assessed by both blinded evaluators and injection investigators at all follow-up visits up to 12 months, GAIS improvement rates, and temporal volume measured by 3D imaging. Aesthetic improvement and participant satisfaction were rated highly at all follow-up visits. PLLA was safe and well tolerated, with no therapy-related adverse events reported.
conclusionsPLLA facial filler effectively improved temple hollowing and achieved aesthetic enhancement for up to 12 months, with an excellent safety profile. LEVEL OF EVIDENCE: 1: (Therapeutic)For image description, please refer to the figure legend and surrounding text.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.